We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $281M
1-Year Est. Return 261.03%
This Fund
S&P 500
This Quarter Est. Return
-21.33%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$847M
AUM Growth
-$205M
Cap. Flow
+$54.3M
Cap. Flow %
6.41%
Top 10 Hldgs %
100%
Holding
10
New
2
Increased
–
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
IMPL
Impel Pharmaceuticals Inc. Common Stock
IMPL
+$33M
2
ELEV
Elevation Oncology
ELEV
+$32.2M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$6.84M
2
APLS
Apellis Pharmaceuticals
APLS
+$4.08M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$273M
$530M 62.6%
9,699,925
– –
HRMY icon
2
Harmony Biosciences
HRMY
$2.04B
$98.9M 11.68%
3,504,624
– –
AKRO
3
DELISTED
Akero Therapeutics
AKRO
$54.6M 6.44%
2,200,778
-243,533
-10% -$6.84M
PHVS icon
4
Pharvaris
PHVS
$2.39B
$42.9M 5.06%
2,303,310
– –
ELEV
5
DELISTED
Elevation Oncology
ELEV
$35.4M 4.18%
+2,608,167
New +$32.2M
APLS
6
DELISTED
Apellis Pharmaceuticals
APLS
$26M 3.07%
411,471
-79,000
-16% -$4.08M
IMPL
7
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$24.4M 2.88%
+2,759,791
New +$33M
CMPI
8
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$21.9M 2.58%
3,673,374
– –
MTCR
9
DELISTED
Metacrine, Inc. Common Stock
MTCR
$11.6M 1.37%
3,059,123
– –
VRNA
10
DELISTED
Verona Pharma
VRNA
$1.06M 0.13%
161,897
– –

Similar funds

FFP
Freedom Financial Partners Oakdale, Minnesota $281M AUM 16.89% 1-Year Est. Return
BDA
Borer Denton & Associates Blue Bell, Pennsylvania $280M AUM 7.09% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
SA
SoundView Advisors Olympia, Washington $281M AUM 17.96% 1-Year Est. Return
ACC
Acorn Creek Capital Fort Collins, Colorado $280M AUM 19.97% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
IP
Investment Partners New Philadelphia, Ohio $281M AUM 20.9% 1-Year Est. Return

venBio Partners's Q2 2021 Portfolio in Review

As of Q2 2021, venBio Partners held 10 positions worth $847M, down 19% from $1.05B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners deployed $54.3M of net new capital in Q2 2021, opening 2 new positions. Its largest new stake was Impel Pharmaceuticals Inc. Common Stock: 2,759,791 shares worth $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Akero Therapeutics, an estimated $6.84M trimmed.

  • venBio Partners's largest Q2 2021 buy was Impel Pharmaceuticals Inc. Common Stock: 2,759,791 shares worth $24.4M.
  • venBio Partners's biggest Q2 2021 reduction was Akero Therapeutics, cutting an estimated $6.84M.
  • venBio Partners's ten largest holdings make up 100% of its $847M portfolio in Q2 2021.
  • venBio Partners opened 2 new positions and closed 0 in Q2 2021.
  • venBio Partners's portfolio value fell 19% quarter-over-quarter to $847M.

Based on venBio Partners's 13F filing for Q2 2021, filed 16 Aug 2021.